LAUNCH OF NEW EchoSolv™ SOLUTION
FOR MITRAL REGURGITATION

Highlights:

- **Artificial Intelligence company Echo IQ introduces new EchoSolv™ module for Mitral Regurgitation**

- **Mitral Regurgitation is the most common type of heart valve abnormality, and is subject to high rates of under-diagnosis**

- **AI-backed decision support solution designed to increase identification of the progression of chronic Mitral Regurgitation**

- **New solution development complete, with availability from August 2023**

- **Sales pipeline for EchoSolv™ continues to grow with new deployments pending**

Sydney: Artificial Intelligence ("AI") and Medical Technology company Echo IQ Limited ("the Company") (ASX:EIQ) is pleased to report the expanding use of the AI-backed EchoSolv™ technology to include the identification of disease progression for the most common heart valve abnormality, Mitral Regurgitation ("MR").

Development of the new MR module is now complete and the technology is being embedded into the EchoSolv™ platform for deployment to new and existing customers in August 2023. The Company has previously announced its intention to incorporate additional diseases into its suite of solutions, and this new module is expected to support users in better identification of chronic Mitral Regurgitation. The introduction of this module also strengthens the commercial case for EchoSolv™ with the technology's expanded capability to support detection of more than one form of structural heart disease, for additional fees. EchoSolv™ is already in use in clinical practice for Aortic Stenosis.

Mitral Regurgitation is the most common form of heart valve disease affecting more than 2% of the US population.[1] The number of people in the US with moderate to severe

---

[1] Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. The Lancet 2006; 368(9540): 1005-11.

MR is expected to double by 2030.[2] Moderate and severe MR is associated with heart failure, heart rhythm problems, frequent hospital admissions and increased risk of death.[3] Despite treatment, in the form of surgical mitral valve repair or replacement, current rates of valve intervention are extremely low.[4]

Echo IQ has developed a novel AI-backed software tool to give EchoSolv™ users an indication of the severity of a patient's chronic Mitral Regurgitation. Without treatment, the prognosis for patients with severe MR is a 1-year mortality rate of 20% and a 5-year rate of 50%.[5] Accurate and timely detection of MR, and its progression, is important in order to correctly identify those patients who might benefit from mitral valve repair and replacement surgeries which have been extensively studied and have shown significant improvement in symptoms and mortality.[6]

Comment

Echo IQ Chief Medical Advisor Professor David Playford said: "This innovation from Echo IQ is an important advance, designed to improve adherence to clinical practice guidelines for mitral regurgitation. The significant amount of data produced in an echocardiogram is distilled simply and clearly by the EchoSolv™ technology and provides an evidence-based output that assists us to make decisions for our patients with mitral regurgitation."

Comment

Echo IQ Executive Chair Andrew Grover said: "We are pleased to be introducing this extension of our EchoSolv™ AI technology even earlier than previously indicated. Adding the classification of Mitral Regurgitation is a positive step forward and shows the adaptability of our technology to cover more diseases. It also means that we can now pursue sales of the AI-backed software that supports improved detection of two forms of heart disease, thus increasing its commercial appeal to cardiologists, hospitals and healthcare facilities. Prior to the launch of the software in August, we expect to report a number of new sales of EchoSolv™ given the strong growth in our sales pipeline recently."

- ENDS –

[2] De Backer O, Piazza N, Banai S, et al. Percutaneous transcatheter mitral valve replacement: an overview of devices in preclinical and early clinical evaluation. Circ Cardiovasc Interv. 2914;7(3):400-409

[3] Mirabel M, Iung B, Baron G, et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J 2007; 28(11): 1358-65.

[4] Cahill TJ, Prothero A, Wilson J, et al, Community prevalence, mechanisms and outcome of mitral or tricuspid regurgitation, Heart 2021;107:1003-1009.

[4] Cahill TJ, Prothero A, Wilson J, et al, Community prevalence, mechanisms and outcome of mitral or tricuspid regurgitation, Heart 2021;107:1003-1009.

[5] Goel et al. Prevalence and outcomes of unoperated patients with severe symptomatic mitral regurgitation and heart failure. J Am Coll Cardiol. 2014 Jan 21;63(2):185-6.

[6] (Douedi S, Douedi H. Mitral Regurgitation. [Updated 2023 Apr 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK553135/)

Authorised for release by the Board of Directors of Echo IQ Limited.

Media Enquiries:
Philip Woolff, Chief Operating Officer
philip.woolff@echoiq.ai / marketing@echoiq.ai / +61 (0)490 030 620

Investor Enquiries:
Andrew Grover, Executive Chair
Andrew.grover@echoiq.ai / investor@echoiq.ai

ABOUT ECHO IQ
Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology.
The company is based in Sydney, Australia.